Close
Close

Ariad Pharmaceuticals - Carcinoma

Partner

Not provided

Rare Disease

Carcinoma

Sponsor

Ariad Pharmaceuticals

Access Program Information

The purpose of this study is to provide brigatinib for those patients with locally advanced and/or metastatic patients with ALK+ NSCLC on an expanded access basis due to their inability to meet eligibility criteria for on-going recruiting trials, inability to participate in other clinical trials (e.g., poor performance status, lack of geographic proximity), or because other medical interventions are not considered appropriate or acceptable.

Contact

Contact: David Kerstein, MD (+1 (617) 494-0400)

Locations
  • United States
  • La Jolla, California, United States
  • Orange, California, United States
  • United States
  • Detroit, Michigan, United States

Free Newsletter